CompletedPhase 3

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

United States462 participantsStarted 2018-12-21

Plain-language summary

To compare the relative efficacy and safety and of 5-FU Cream to the marketed formulation Efudex® (5-FU) Cream, and to demonstrate the superior efficacy of the two active formulations over that of the Vehicle Control Cream, in the treatment of actinic keratosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male and female 18 years of age and older.
✓. Subject is able to understand and willing to sign Institutional Review Board (IRB) approved written informed consent for this study.
✓. Subject must be generally healthy, based on medical records, and free from any clinically significant disease, other than AK, that in the opinion of the investigator might interfere with the study evaluations.
✓. At least five (5) and no more than ten (10) clinically typical, visible or palpable, discrete AK lesions, each at least 4 mm in diameter on the face (excluding ears), forehead or bald scalp.

Exclusion criteria

✕. Subject is pregnant, lactating, or is planning a pregnancy within the period of study participation.
✕. Subject suffers from excessive alcohol consumption, drug abuse or has a condition that could compromise the subject's ability to comply with study requirements.
✕. Presence of Atopic Dermatitis, Basal Cell Carcinoma, Eczema, Psoriasis, Rosacea, Squamous Cell Carcinoma or other possible confounding skin conditions on the

What they're measuring

treatment success

Timeframe: week 6

Trial details

NCT IDNCT03727074

SponsorSol-Gel Technologies, Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-12-19

View on ClinicalTrials.gov More Actinic Keratosis (AK) trials